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Prospective study of
gentamicin locking of
tunnelled dialysis catheters:
The effect on infection rates
and CRP
To the Editor: Furthering the study recently published
from this unit on the utility of antibiotic-locking of tun-
nelled dialysis catheters [1], we report data obtained from
the unitwide adoption of this policy. Tunnelled catheters
are widely used for hemodialysis access, but their use is re-
stricted by catheter-related infection (CRI) [2]. Our orig-
inal randomized controlled study indicated that using a
combination of gentamicin and heparin for prophylactic
filling of new catheters was effective at reducing CRI [1].
All catheters in use at baseline were included, and had
been locked using 5000 IU/mL of heparin in saline only
for the preceding three months. After a two-month ob-
servation period, catheters were locked with gentamicin
(gentamicin 5 mg/mL, heparin 5000 IU/mL).
Forty-eight patients were included. Nine infections oc-
curred in eight patients in the observation period, five
in previously uninfected catheters. In comparison, 44 pa-
tients were studied in the two months following the intro-
duction of gentamicin locking. Two infections occurred
in two patients, none in previously uninfected catheters.
Overall, the rate of CRI dropped from 3.12/1000 catheter
days to 0.76/1000 catheter days (P < 0.05). CRP levels
were lower following the introduction of gentamicin lock-
ing (31.6 compared with 20.4 mg/L; P < 0.05). No organ-
isms were resistant to gentamicin.
These data are consistent with our original study, in
which CRI decreased from 4/1000 to 0.3/1000 catheter
days with gentamicin [1]. Levels of CRP dropped, indi-
cating an overall reduction in the inflammatory burden.
In a prevalent population of catheters, locking with
gentamicin is an effective means of reducing the rate of
CRI, and reduces CRP levels.
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Analgesic use in hemodialysis
patients: Osler at the bedside
and computer-generated data
To the Editor: We were disappointed in Dr. Baille’s
study design, analysis, and conclusion that analgesics are
underprescibed [1]. We investigated the use of intra-
venous analgesics in patients on hemodialysis [2], and
found that the most commonly used drugs were notorious
for serious problems. l−Agonists with active metabolites
that are renally excreted can cause unpredictable levels of
activity with life threatening complications. Dr. Baillie’s
report makes no distinction in types of narcotics, receptor
affinity, route of metabolism and excretion, the presence
of active metabolites, nor does he examine any analgesic
complications other than those for NSAIDs.
Similarly, since the authors make no distinction in the
various types of pain, they cannot distinguish patients
who were crippled from severe coronary artery disease
or diabetic patients with neuropathic pain. Yet while
the chest pain might be appropriately treated with ni-
trates, and the neuropathic pain might be well treated
with tricyclics, those patients would be considered un-
treated by the authors because they were not treated with
analgesics.
Finally, the suggestion that analgesics were underpre-
scribed is astounding. Dr. Baillie’s presumption that the
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authors evaluating the computer analysis knew how to
better treat the pain of these patients than the nephrol-
ogist at the bedside suggests an unmerited confidence.
Without consultation with the patients at the bedside, a
blind guideline suggested by the authors could be po-
tentially lethal. We always wish to encourage young in-
vestigators, and suggest that they should re-evaluate their
study and develop a design that includes some evaluation
of the pain and its treatment at the bedside. As William
Osler noted, “The hospital is the only proper place to rear
a true disciple of Aesculepius.”[3]
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Reply from the Authors
Dr. Diskin raises several interesting points. However,
as an observational study, the DOPPS cannot provide
the type of analysis suggested—evaluating the type of
pain experienced and the corresponding use of different
agents. The observational nature of the DOPPS dataset
has been well described, and its numerous publications
have examined associations and correlations of outcomes
with a constellation of variables. Our study addressed
many outcomes and variables associated with analgesic
use. The introduction clearly states that there are poten-
tial problems associated with the use of analgesics in in-
dividuals with diminished or no kidney function and pro-
vides a thorough list of potential problems.
Dr. Diskin correctly points out that we made no dis-
tinction in the various types of pain, and thus, cannot dis-
tinguish patients who were crippled from severe coronary
artery disease or diabetic patients with neuropathic pain.
We have reanalyzed our data to examine self-reported
pain and the use of analgesics at baseline, omitting those
patients with angina and peripheral neuropathy. Interest-
ingly, there were no substantial differences in the findings.
The proportion of patients reporting moderate to very se-
vere pain within the last four weeks having received no
analgesics changed from 73.8% (original) to 74.3% (with
angina and peripheral neuropathy excluded). Similarly,
the proportion of those responding that pain interfered
with their normal work to a moderate to extreme ex-
tent with no analgesic prescription changed from 74.7%
(original) to 74.4% (with exclusions). Thus, Dr. Diskin’s
hypothesis does not appear to be supported by these new
analyses.
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